ReviewCureus2026
Endometriosis-Associated Implantation Failure: Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implantation failure remains a major challenge in assisted reproductive technology (ART) and is a significant contributor to infertility in women with endometriosis. Beyond mechanical distortion and ovarian dysfunction, increasing evidence suggests that endometriosis profoundly alters endometrial receptivity through complex inflammatory, immunological, and molecular mechanisms. Chronic inflammation, progesterone resistance, dysregulated immune cell populations, and aberrant cytokine signaling converge to create a hostile endometrial microenvironment that compromises embryo-endometrial crosstalk and implantation success. This narrative review provides a comprehensive overview of the pathophysiological pathways linking endometriosis to implantation failure, with particular emphasis on immune dysregulation and defects in endometrial receptivity. We summarize the current evidence regarding key immune cell populations, including uterine natural killer (uNK) cells and macrophages, and their role in modulating implantation. We further discuss established and emerging biomarkers of impaired receptivity, including BCL6, integrins, endometrial receptivity assays, and epigenetic markers, highlighting their diagnostic potential and current limitations. Finally, we review contemporary and emerging therapeutic strategies aimed at restoring endometrial receptivity in women with endometriosis-associated implantation failure. These include hormonal pretreatment protocols, immunomodulatory approaches, and novel regenerative therapies such as platelet-rich plasma (PRP) and granulocyte colony-stimulating factor (G-CSF). By integrating mechanistic insights with clinical evidence, this review aims to provide a practical framework for the personalized management of implantation failure in women with endometriosis and to identify key directions for future research in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.